How Blue Goat Cyber Keeps Medical Device Security FDA-Ready with Zero Rejections
Christian Espinosa, Founder & CEO of Blue Goat Cyber, shares how his firm carved out a focused niche in medical device cybersecurity. By specializing exclusively in FDA regulatory needs, they’ve maintained a perfect record on submissions and built growth through targeted services and client trust.
In this edition of the Ecommerce Authority Playbooks series, we dive into how
Blue Goat Cyber grows, retains customers, and prepares for the future of search in 2026 and beyond.
The interview
1. What’s the quick origin story of your brand, and what makes your product or positioning genuinely different from other options in your niche?
Christian Espinosa: Blue Goat Cyber started because I saw a gap that most general cybersecurity firms weren’t built to fill. I’d already founded and sold Alpine Security, a broad penetration testing firm, and through that work kept encountering medical device manufacturers who needed something more specific than a standard pen test report, they needed documentation that could actually get them through FDA cybersecurity review. In 2022, a health scare made the stakes personal for me too, six blood clots, caught in time by a portable Doppler ultrasound, a piece of connected medical technology that worked because it was secure. That experience settled it, and I built Blue Goat Cyber to only serve medical device manufacturers, nothing else.
What makes us genuinely different is that we don’t do general IT security at all. Most cybersecurity firms will take on a medical device client as one project among many industries, but we build every service, threat modeling, SBOMs, penetration testing, deficiency response, specifically around what an FDA reviewer needs to see in a 510(k), De Novo, or PMA submission. That narrow focus is why we’ve been able to hold a zero cybersecurity rejection record across more than 250 submissions.
2. Since launch, what have been the 1-2 real turning points for your brand-specific decisions, pivots, or experiments that noticeably changed your growth or profitability-and what did you learn from them?
Christian Espinosa: The first real turning point was building a dedicated FDA deficiency response service instead of only offering premarket work. We kept getting calls from manufacturers who’d already submitted through another firm or in-house team and gotten hit with an FDA cybersecurity deficiency letter, panicked because they were burning through their 180-day response window. Once we built a process to diagnose those gaps fast, our claim is within 48 hours, and fix them without the client losing their place in the queue, that became a major growth driver, since it brought in clients who hadn’t originally been shopping for a premarket partner.
The second turning point was launching GoatWatch, our own SBOM risk management product, once we realized postmarket monitoring was where a lot of clients quietly struggled after clearance. What I learned from both moves is that the biggest opportunities weren’t in marketing harder to the same audience, they were in noticing where our existing clients had unmet needs adjacent to the service they’d originally hired us for.
3. Which 2-3 channels drive most of your revenue right now (for example SEO, paid social, email, marketplaces, influencers), and what have you learned about making those channels work in your category?
Christian Espinosa: Referrals and industry reputation drive most of our revenue, specifically manufacturers referring us to other manufacturers, consultants, and regulatory affairs teams they work with. What I’ve learned is that in a niche this specific, word of mouth carries more weight than almost any paid channel could, because the people making the buying decision are regulatory and quality teams who trust peer recommendations over advertising, especially for something as high-stakes as an FDA submission.
The second channel is speaking and thought leadership at industry events like MedTech World and LSI summits, along with resources like Code Blue Chart, our public database tracking MedTech cybersecurity incidents and recalls. What’s worked about this channel specifically is that it doesn’t feel like marketing to the audience, it positions us as the firm tracking the industry’s actual security incidents, so when a manufacturer gets a deficiency letter, we’re already the name they think of.
4. How are you thinking about search in 2026 – Google, AI assistants like ChatGPT, and other discovery platforms? What, if anything, have you changed in your content or site to stay visible as AI search grows?
Christian Espinosa: Our buyers, regulatory affairs leads and quality teams at device manufacturers, are increasingly asking AI assistants direct questions like what’s needed for an FDA cybersecurity submission or how to respond to a deficiency letter, so we’ve shifted our content to answer those exact questions clearly rather than burying the answer under generic SEO padding. We’ve leaned into resources like Code Blue Chart, our public database of MedTech cybersecurity incidents and recalls, because that kind of structured, factual content tends to get pulled into AI-generated answers in a way that vaguer marketing copy doesn’t.
The bigger change has been writing content the way a regulatory professional actually talks and searches, specific terms like Section 524B, eSTAR, SBOM, threat modeling traced to ISO 14971, rather than softer marketing language. AI search tools seem to reward specificity and clear factual structure over persuasive copy, so our site now reads more like a reference resource for the regulatory pathway itself, which happens to also be exactly what our clients need before they ever talk to a salesperson.
5. What do you do to turn first‑time buyers into repeat customers and advocates? Are there specific experiences, content, or community touches that work especially well for you?
Christian Espinosa: Our postmarket support is what turns a one-time FDA submission client into a long-term relationship. Once a device clears, we stay involved through ongoing SBOM monitoring, vulnerability response, and a named team rather than a help desk, so when a new vulnerability surfaces in a component eighteen months later, the manufacturer already has a relationship with people who understand their specific device rather than starting over with a new vendor.
The advocacy piece comes from how directly our work protects something manufacturers care about deeply, getting their device to market on time and keeping patients safe. When we resolve a deficiency letter fast enough that a client doesn’t lose their queue position, or when GoatWatch flags a vulnerability before it becomes a real incident, that’s the kind of tangible save that turns a client into someone actively referring us to other manufacturers, which is still our single biggest growth channel.
6. If you had to write a short playbook for an ecommerce founder one stage behind you, what would you double down on over the next 12 months – and what would you stop doing entirely?
Christian Espinosa: I’d tell them to double down on going narrow before they feel ready to. We didn’t become a credible name in MedTech cybersecurity by serving every industry a little bit, we became credible by refusing general IT security work entirely and building deep expertise in exactly one regulatory pathway. A founder one stage behind us should identify the one niche where their existing skills give them a genuine, hard-to-copy advantage, and then stop taking on adjacent work just because it pays the bills in the short term.
What I’d tell them to stop doing entirely is chasing volume before they’ve built a track record they can point to. We built our credibility on a specific, provable number, zero cybersecurity rejections across 250-plus FDA submissions, and that number only exists because we said no to clients and projects outside our focus early on. Founders one stage behind often want to say yes to everything to survive, but every unfocused client is a distraction from building the one proof point that will actually convert future customers faster than any ad spend could.
ecommerce journey and insights with Leaders Perception’s readers.
Want to share your ecommerce playbook?
If you run an online brand and would like to be featured in a future Ecommerce Authority Playbooks interview,
you can submit your story and details here. It’s 100% free and takes just a few minutes.